Seed Therapeutics

Executive Summary

Seed Therapeutics is a pioneer in targeted protein degradation, leveraging its proprietary RITE3™ platform to design molecular glue degraders that systematically match disease-causing proteins with E3 ubiquitin ligases. Founded in 2018 and headquartered in Cambridge, Massachusetts, the company focuses on creating novel therapeutics for oncology, neurodegeneration, and immunology. By harnessing the full human repertoire of E3 ligases, Seed Therapeutics aims to address previously undruggable targets, offering a transformative approach to treating complex diseases. Its platform enables de novo design of small molecule glues that induce proximity between a target protein and an E3 ligase, leading to ubiquitination and subsequent degradation. Currently in Phase 3 clinical development, Seed Therapeutics is advancing its lead oncology program, which targets a well-validated oncogenic driver. The company has demonstrated promising preclinical and early clinical data, supporting its potential to become a best-in-class therapy. With a strong intellectual property portfolio and ongoing collaborations, Seed Therapeutics is well-positioned to capitalize on the growing interest in protein degradation. Key upcoming milestones include the readout of pivotal Phase 3 data, potential regulatory submissions, and expansion of its pipeline into additional indications, particularly in neurodegeneration. The company's innovative platform and strategic focus on high-value targets underpin its potential to deliver significant value to patients and shareholders.

Upcoming Catalysts (preview)

• Q3 2026Phase 3 Top-Line Data Readout for Lead Oncology Program65% success
• Q4 2026IND Filing for First Neurodegeneration Program70% success
• Q2 2026Strategic Partnership or Licensing Deal for RITE3™ Platform60% success